Symptom assessment AI
Ada Health
Ada’s direct assessments differ from partner-controlled sharing and decisions. Its US policy describes consented health-derived marketing segments. Removing an existing segment requires a separate request, beyond changing the consent setting.
Checklist assessment dated October 30, 2026. Independent confirmation is incomplete. Hugo has not personally verified this service.
Agency checklist · October 30, 2026
Leans expands 8 of 12 yes
Document-based draft. Independent confirmation is incomplete. Hugo has not personally verified this service.
Assessed function: Direct Ada symptom assessment (Ada Assess) used by the patient on ada.com or the Ada app. Partner-embedded Assess and the US advertising-segment consent are distinguished in notes.
A no can mean missing documentation or institution-dependent control; it does not by itself establish harmful behavior. These categories are not clinical safety or product-quality ratings.
- Public documents do not establish actual product behavior.
- The independent review screened rules and selected evidence; it did not replicate all twelve answers for this tool.
See all twelve answers and their evidence
| Question | Answer | Evidence / review | Source and reasoning |
|---|---|---|---|
| 1. Told it is AI | Yes | documented Not independently replicated | Ada Assess is an AI software application that uses custom probabilistic reasoning technology on a medical-expert-curated knowledge baseSource Terms section 1.3 also describes 'an in-house developed, artificial intelligence (AI) model'. Last modified 6 Nov 2025. |
| 2. Operator and model maker named | Yes | documented Not independently replicated | Ada utilizes the services of Together AI, a third party LLMSource Ada Health, Inc. (US) and Ada Health GmbH are named. The core model is Ada's own PGM. Together AI (LLM) and Microsoft Azure (free-text input) are named. |
| 3. Patient chooses to use it | Yes | documented Not independently replicated | Ada Assess is available for free via our website and (when and where available) via websites/apps of business partners.Source Direct use is the user's choice. In partner-embedded versions the partner chooses to deploy it, and I did not assess that variant. |
| 4. Patient sets the task | Yes | documented Not independently replicated | to provide Users with health information relevant to medical findings they are currently experiencingSource The user supplies the symptoms. The fixed function is symptom assessment, with Ada's questions and an optional partner-care step. |
| 5. Patient can decline or stop | Yes | documented Not independently replicated | You are entitled to stop using this website, Ada Assess, Ada PHC and your User Account at any timeSource Self-started tool per the Q3 source, no care depends on it. |
| 6. Patient sees the AI output | Yes | documented Not independently replicated | the User is provided with a report that lists such information as the conditions likely to be causing these findingsSource The Ada Health GmbH policy says the report can be downloaded to the device. |
| 7. Patient can correct or challenge | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Source The policies list GDPR/CCPA rights to rectify personal data, but no route to correct or contest the assessment output is documented. |
| 8. Patient can get a copy | Yes | documented Not independently replicated | You are not required to receive the report this way and can instead download the report onto your device.Source This is the Ada Health GmbH (app) policy. It also lists data portability rights. |
| 9. Patient can delete | Yes | documented Not independently replicated | you may request the deletion of a specific case or delete the case yourselfSource The GmbH policy says data is deleted or irreversibly anonymized within 1 month. The US terms say deactivation deletes personal data but Ada keeps rights to anonymized data. |
| 10. Training or sale does not override patient choice | No | documented Not independently replicated | To improve our Services, as well as for training and quality purposesSource The US policy says third-party LLMs will not train on user data. But terms 5.2 say Ada uses Together AI 'for internal AI training', the policy lists developing 'Artificial Intelligence/Large Language Models', and the GmbH policy trains on anonymized assessment data. No opt-out is documented. |
| 11. Patient can run it or take it elsewhere | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Source Vendor-hosted only. |
| 12. No advertising or data business | No | documented Not independently replicated | Ada also creates advertising segments which it sells to its marketing partners.Source US policy section 6.2 makes this consent-based, but the rule counts it even with consent. Terms 3.2 grant Ada a perpetual license to use anonymized data 'in any manner'. Conflict: the GmbH app policy says Ada will 'never share your personal health information with advertisers'. The US policy governs for US users. |
Initial coding: Claude Sonnet helpers, compiled by Claude Opus 5.5 (Anthropic). Selective review and corrections: GPT-6 Astra (OpenAI). Editor: Hugo Campos. Acceptance of corrections is not product verification.
Checklist rules · Independent review and limitations · Later evidence follow-up
Earlier v1.3 assessment and control finding
Historical assessment under different rules. It does not set the current checklist zone.
Agency finding, before method v1.3
Mixed, potentially agency-expanding
Legacy editorial placement, pre-method: 66
This profile has not yet been reviewed under the published method. Its finding and any number are editorial placements made before the method existed.
- Evidence
- Documentary review. Public sources only, no hands-on testing by HugoScore.
- Review status
- AI draft. No person has settled the findings.
Earlier evidence and assessment
The sections below preserve the earlier review. Its classifications and provenance are historical; the checklist above gives the current draft classification.
Earlier finding · Legacy editorial placement, pre-method: 66
Method v1.3. The control line is evidence for how the agency finding arose, not a quality score. Legacy editorial placement, pre-method: 66. Not comparable with v1.3 positions.
Mixed, potentially agency-expanding
Ada’s direct assessments differ from partner-controlled sharing and decisions. Its US policy describes consented health-derived marketing segments. Removing an existing segment requires a separate request, beyond changing the consent setting.
Patient agency
How this tool changes agency
Reports support reflection and action. Correcting personal data and contesting an institution's consequential decision are separate routes, and actual report-level revision remains untested.
In-app consent comprehension, report correction and partner alternatives remain unverified
Patient agency assessment
Who sets and changes the goal?
Direct assessment can support self-directed care seeking. Mandatory sharing in some integrations is an actual deployment condition, while partner routing decisions are not attributable to every consumer assessment.
What can the patient understand, question, or do?
Reports support reflection and action. Correcting personal data and contesting an institution's consequential decision are separate routes, and actual report-level revision remains untested.
Can the patient evaluate the conditions of use?
The separate segment-removal action materially affects meaningful withdrawal. Pseudonymization should not be described as the absence of health-derived commercial targeting.
Text findings
Conditions of use
Published controls and their limits
The separate segment-removal action materially affects meaningful withdrawal. Pseudonymization should not be described as the absence of health-derived commercial targeting.
What remains unknown?
Not tested or not established
In-app consent comprehension, report correction and partner alternatives remain unverified
Who evaluated this?
AI-assisted public-source draft
Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.
Sources checked
Source-specific findings and retrieval limitations are recorded in the full report.
Earlier review provenance
Criteria
CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.
Reviewer
AI-assisted public-source reassessment prepared in OpenAI Codex.
AI / model
OpenAI Codex / GPT-6
Human review
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
Review date
2026-09-08
Limitations
In-app consent comprehension, report correction and partner alternatives remain unverified No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.
Earlier review method
Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
Document-based draft · Moderate for policy distinctions (AI-assisted draft)